Spravato has been approved since 2019 for TRD, with its label extended the following year as a rescue therapy for adults with major depressive disorder (MDD) who were at risk of self-harm or suicide.

Johnson & Johnson has priced its new Spravato nasal spray for treatment-resistant depression (TRD) too high to offer value for money, says a US cost-effectiveness body. The Institute for Clinical ...

The Food and Drug Administration (FDA) recently expanded approval for Spravato, an antidepressant nasal spray used to treat depression. Parkside Psychiatric Hospital has a Spravato outpatient clinic ...

The Food and Drug Administration (FDA) recently expanded approval for Spravato, an antidepressant nasal spray used to treat depression. Parkside Psychiatric Hospital has a Spravato outpatient ...